Member Info for Leggster

I have not posted here for a while, but I agree Potnak the longer we run silent the stronger the assumption that tox study is going well will grow. I personally still believe a deal will follow successful completion of the tox study. If we get positive news on 737, a partnership on 1802, the peer review or more on BBB/CNS molecules then we could be looking at a strong exit from 2026.

Not intended for your comments Matty, you are consistent and I'm sure a genuine holder. Hopefully we will all see our investments back and a good return, eventually....

Yes looks like a further delay, very frustrating, some dubious posts from doomsters after the news who IMO are posting for questionable motives. Will listen in on Thurs and form a view then hopefully after some facts are shared.

The board feels very despondent, I look at this in a different way for me no release of the peer review, no news on 1802, no news on 737, the introduction of the Tox study, the investigation of CNS indications. I feel these are all pointers to a TO. For me we are not letting the cat out of the bag on 1801, the partner may want 737 and 1802 therefore no moves needed on these fronts, the Tox study results maybe a prerequisite to a deal and the CNS molecules proof that SKIL has value, I contend that the board are working steadily towards a great outcome. These moves on non material and certainly not bad news should be ignored. Waiting tests the nerves for those without the stomach to accept that there are known unknowns. Business is about constant prioritisation, dates change that is the nature of prioritisation and business particularly in development. GLA

I completely agree Laz, the salaries are in no way excessive and I also agree they could earn more elsewhere without the stress of running a small biotech. They clearly want to achieve something meaningful. They have for me done a great job on the science, the coming weeks/monthly will show if they will deliver again for shareholders. GLA

Potnak on the science I am always confident I feel certain that it will be fine, the rest is normally more of a concern. On this occasion though I am hoping that the TOX results are a prerequisite to a deal of some kind, I prefer a TO but am fine with a license. GLA

I am in your camp on warrants I really do not understand what is gained by exercising early. GLA

The recent BBC coverage of Varda, looking to manufacture drugs in low gravity, was interesting. Low gravity can offer solutions to solubility issues (according to my AI research)

Unfortunately it's expected to be another decade before this type of option becomes reality.......

Potnak, My son went to York as well studying Economics and the cost of renting there is shocking, he finished last year and the cost save is very comforting....let's hope this investment delivers what we hope

HBD a great read and find

At least it has triggered a small pickup in volume, will be interesting to see what develops over the next few days

Mafuta fair point on the costs

Not the RNS we were expecting but that's what makes investing fun, AI IMO is definitely the direction to investigate and starts to explain the BBB announcement. But why no cost to SAR. Is this influenced by a partner in the wings, an AI search suggests they have a relationship with an unnamed medium sized Pharma and one large Pharma. I hope this collaboration has been put in play by a partner. GLA

Waiting is becoming tedious, but comes with the territory for this type of investment. Massively frustrating but I still trust the science and see the potential returns as material. 737, 1801, 1802 BBB molecules, SKIL platform and even the insoluble FLT3 together offer a tempting set of assets. No marketing, no press releases, no peer results. For me this can only mean negotiation in the background, but still a very frustrating wait....

JMAX I agree it is not a level playing field the PI cannot hope to be the velocity traders. That's why I invest long in areas that interest me and I think are good bets, for me 25% in safe 50% in medium risk 25% in high risk. SAR is in my high risk category if I lose on the 25% I see it as no regrets. When I retire I will take a more conservative strategy. If I have to wait a decade or more then I am prepared to hold. For me I try and buy early and average down during dilution and dips then top slice, biotech is great with the testing cycle for that as a strategy IMO. GLA

I assume that they had probably reached the expiry date otherwise I agree you would hold. GLA

Duggan likes a deal, the $5bn he paid the Chinese for ivonescimabb was a brave gamble, our pipeline could fit neatly in their model. They are likely to have plenty of cash shortly depending on the size of the initial payment. Wishful thinking but you have to have hope.

Have had it for about 8 years, had mentally put it in the bottom draw, but it has come good, on its re-rate last year I took out my original investment , so it is now a free ride. I still hold a few thousand shares so am hoping for a good few weeks, on a decent rise might put some of the profit in SAR. GLA

Flipping discussion back to investments, one of my other investments SUMM looks like re-rating upwards on the back of a rumour of a $15bn license with Astra Zenica, it's a much later stage cancer drug. With that additional war chest from a deal perhaps a call from SP to Robert Duggan to tell him about 1802 might be an option. GLA

Yes nothing to dislike in the presentation everything seems to be moving forward. I felt that his commentary on all molecules was good. I would though have liked to have heard something on why the recent dabble with molecules crossing the BBB. The silence on this increases my belief that it was at the request of a suitor to prove that SKIL has some value. GLA